Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Brilaroxazine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Brilaroxazine, 1239729-06-6, X8l60ba01i, 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo[b][1,4]oxazin-3(4h)-one, 2h-1,4-benzoxazin-3(4h)-one, 6-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-, 2h-1,4-benzoxazin-3(4h)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-
    Molecular Formula
    C22H25Cl2N3O3
    Molecular Weight
    450.4  g/mol
    InChI Key
    PMKMNTBZJOXTJW-UHFFFAOYSA-N
    FDA UNII
    X8L60BA01I
    Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III clinical trials for schizophrenia.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4H-1,4-benzoxazin-3-one
    2.1.2 InChI
    InChI=1S/C22H25Cl2N3O3/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28)
    2.1.3 InChI Key
    PMKMNTBZJOXTJW-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CN(CCN1CCCCOC2=CC3=C(C=C2)OCC(=O)N3)C4=C(C(=CC=C4)Cl)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    X8L60BA01I
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Brilaroxazine

    2. 1239729-06-6

    3. X8l60ba01i

    4. 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo[b][1,4]oxazin-3(4h)-one

    5. 2h-1,4-benzoxazin-3(4h)-one, 6-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-

    6. 2h-1,4-benzoxazin-3(4h)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-

    7. 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo(b)(1,4)oxazin-3(4h)-one

    8. Brilaroxazin

    9. Brilaroxazine [inn]

    10. Unii-x8l60ba01i

    11. Brilaroxazine [who-dd]

    12. Schembl3404085

    13. Bdbm312188

    14. Dtxsid001136921

    15. Db09226

    16. Rp-5063

    17. Us9604944, 15b (example 14)

    18. Hy-109112

    19. Cs-0077721

    20. 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-2h-1,4-benzoxazin-3(4h)-one

    21. 6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4h-1,4-benzoxazin-3-one

    22. 2036070-48-9

    2.4 Create Date
    2010-09-07
    3 Chemical and Physical Properties
    Molecular Weight 450.4 g/mol
    Molecular Formula C22H25Cl2N3O3
    XLogP34.4
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count7
    Exact Mass449.1272971 g/mol
    Monoisotopic Mass449.1272971 g/mol
    Topological Polar Surface Area54 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity562
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for the treatment of schizophrenia and schizoaffective disorder.